Loading
Robert Fenstermaker invented SurVaxM, a survivin-targeted vaccine in late-stage trials for glioblastoma.
Robert A. Fenstermaker is Chair of the Department of Neurosurgery and Director of the Neuro-Oncology Program at Roswell Park Comprehensive Cancer Center. He is a neurosurgeon-scientist known for inventing SurVaxM, a survivin peptide mimic vaccine for glioblastoma that showed encouraging phase 2 results and advanced to a randomised trial in newly diagnosed disease. His selected paper reports the phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma. He continues to work on cancer vaccines and glioma while leading neurosurgery at Roswell Park.
| Title | Journal | Year |
|---|---|---|
| Phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma | Journal of Clinical Oncology | 2023 |
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.
Shares Off-the-shelf cancer vaccines, Glioma & glioblastoma.